Novo Nordisk shares fall as Wegovy pill sales miss forecasts
Novo Nordisk raised its full-year guidance for obesity and diabetes drugs but its US shares declined after the Wegovy weight-loss pill's sales did not meet analyst expectations.
Kurz gefasst
Novo Nordisk raised its annual outlook for obesity and diabetes drugs. Shares in the Danish company fell after sales of its Wegovy weight-loss pill did not meet forecasts.
Novo Nordisk raised its full-year guidance for obesity and diabetes drugs.2,1 The company raised its forecasts for the second time in 2026.1 Novo Nordisk's US shares fell after sales of the Wegovy weight-loss pill did not meet analyst expectations.1
The Wegovy pill is a weight-loss medication developed by Novo Nordisk.2,1 Analysts had expected higher sales of the Wegovy pill.1
Warum es zählt
- Mehr zu
- Stocks
Dieser Text entstand aus den unten aufgeführten 2 Berichten von 2 unabhängigen Medien und wurde Zeile für Zeile mit ihnen abgeglichen. Er ist keine Kopie eines einzelnen davon. Fehler entdeckt? Sagen Sie es uns.
Discussion
0Comments are screened automatically. Disagreement is fine; abuse and spam are not.
Loading…
Related
Novo Nordisk verliert die Führungsposition bei GLP-1-Medikamenten an Eli Lilly
Der dänische Pharmariese Novo Nordisk sah seine Vorherrschaft bei GLP-1-Medikamenten zur Gewichtsreduktion durch den US-Konkurrenten Eli Lilly in Frage gestellt, nachdem dieser bahnbrechende neue Therapien auf den Markt gebracht hatte.
SK Hynix shares rise on buyback speculation
SK Hynix shares advanced after overnight gains in US chipmakers and reports of a potential shareholder return plan.
Alexander Hatley from Spring, Texas, USA / CC BY 2.0SpaceX revenue jumps 92% in first earnings after IPO
SpaceX reported $7.8 billion in quarterly revenue, a 92% increase, but posted a $541 million net loss in its first earnings report since going public in June.
FDV / CC BY-SA 4.0AstraZeneca shares drop after $400bn Bristol-Myers deal talks
A potential $400bn merger between AstraZeneca and Bristol-Myers Squibb would create the world's fourth-largest drugmaker but faces investor skepticism.